Image 3_Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.tif

Image 3_Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.tif

Introduction<p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for advanced cancers, yet their efficacy remains heterogeneous among patients. Tumor mutation burden (TMB) has been extensively explored as a potential biomarker for predicting ICI response. However,...

Full description

Saved in:
Bibliographic Details
Main Author: Wuyuan Liao (21776432) (author)
Other Authors: Xinwei Zhou (6176357) (author), Hansen Lin (805525) (author), Zihao Feng (3538655) (author), Xinyan Chen (758454) (author), Yuhang Chen (584479) (author), Minyu Chen (14821353) (author), Mingjie Lin (11957492) (author), Gaosheng Yao (15859679) (author), Jinwei Chen (784194) (author), Haoqian Feng (21776450) (author), Yinghan Wang (2062750) (author), Zhiping Tan (233498) (author), Youyan Tan (21776453) (author), Jun Lu (36049) (author), Pengju Li (2553166) (author), Jinhuan Wei (301339) (author), Li Luo (149019) (author), Liangmin Fu (13885353) (author)
Published: 2025
Subjects:
Genetic Immunology
immune checkpoint inhibitor
tumor mutation burden
tumor microenvironment
pan-cancer
biomarker
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items